Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $165.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lifted by Robert W. Baird from $110.00 to $165.00 in a research report released on Monday, The Fly reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Ultragenyx Pharmaceutical from a buy rating to a hold rating in a research report on Thursday, January 7th. ValuEngine downgraded shares of Ultragenyx Pharmaceutical from a buy rating to a hold rating in a research report on Tuesday, December 1st. Barclays increased their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $176.00 and gave the stock an overweight rating in a research report on Monday. Bank of America cut shares of Ultragenyx Pharmaceutical from a buy rating to a neutral rating and increased their price objective for the stock from $104.00 to $126.00 in a research note on Thursday, November 12th. Finally, Evercore ISI reissued an in-line rating and issued a $110.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Ultragenyx Pharmaceutical presently has an average rating of Buy and an average price target of $102.12.

RARE opened at $134.71 on Monday. Ultragenyx Pharmaceutical has a 1-year low of $31.99 and a 1-year high of $179.65. The company has a market capitalization of $8.22 billion, a PE ratio of -25.81 and a beta of 2.18. The firm’s 50 day simple moving average is $144.59 and its two-hundred day simple moving average is $103.23.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, October 27th. The biopharmaceutical company reported ($1.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.28) by $0.15. Ultragenyx Pharmaceutical had a negative net margin of 188.51% and a negative return on equity of 56.12%. The business had revenue of $81.47 million for the quarter, compared to the consensus estimate of $55.18 million. As a group, research analysts expect that Ultragenyx Pharmaceutical will post -5.49 earnings per share for the current year.

In related news, CEO Emil D. Kakkis sold 30,000 shares of the firm’s stock in a transaction on Monday, January 4th. The shares were sold at an average price of $136.90, for a total transaction of $4,107,000.00. Also, SVP Theodore Alan Huizenga sold 4,000 shares of the firm’s stock in a transaction on Thursday, January 7th. The shares were sold at an average price of $140.65, for a total transaction of $562,600.00. Following the transaction, the senior vice president now directly owns 20,436 shares of the company’s stock, valued at $2,874,323.40. The disclosure for this sale can be found here. Insiders have sold 44,000 shares of company stock valued at $5,670,788 over the last ninety days. 8.20% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the business. Private Advisor Group LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth $47,000. Point72 Hong Kong Ltd purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $57,000. HighMark Wealth Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 615.8% in the 3rd quarter. HighMark Wealth Management LLC now owns 723 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 622 shares in the last quarter. Harbor Investment Advisory LLC grew its stake in shares of Ultragenyx Pharmaceutical by 69.7% in the 3rd quarter. Harbor Investment Advisory LLC now owns 750 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 308 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth $68,000.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Article: How to identify percentage decliners

The Fly

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.